

(51) International Patent Classification:
C07K 14/545 (2006.01) *A61P 19/02* (2006.01)(21) International Application Number:
PCT/US2011/045995(22) International Filing Date:
29 July 2011 (29.07.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/368,799 29 July 2010 (29.07.2010) US
61/436,178 25 January 2011 (25.01.2011) US
61/436,184 25 January 2011 (25.01.2011) US
61/493,966 6 June 2011 (06.06.2011) US
61/493,967 6 June 2011 (06.06.2011) US(71) Applicant (for all designated States except US):
ELEVEN BIOTHERAPEUTICS, INC. [US/US]; 215
First Street, Suite 400, Cambridge, MA 02142 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **BARNES, Thomas, M.** [AU/US]; 215 First Street, Suite 400, Cambridge, MA 02142 (US). **HOU, Jinzhao** [US/US]; 215 First Street, Suite 400, Cambridge, MA 02142 (US). **KING, Bracken, M.** [US/US]; 215 First Street, Suite 400, Cambridge, MA 02142 (US).(74) Agent: **HATTON, Allyson, R.**; Lando & Anastasi LLP,
Riverfront Office Park, One Main Street, Suite 1100,
Cambridge, MA 02142 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

[Continued on next page]

(54) Title: CHIMERIC IL-1 RECEPTOR TYPE I AGONISTS AND ANTAGONISTS

**FIG. 1**(57) Abstract: Featured herein are non-naturally occurring cytokine domains that can be used, *inter alia*, to modulate cellular signalling responsive to interleukin-1 receptor I (IL-1 RI), to treat disorders, and to detect and/or bind to cellular receptors, as well as other agents. Exemplary cytokine domains can contain amino acid residues from at least two parental cytokines domains, for example, receptor binding features, surface features, β strands, and loops from at least two parental cytokines domains.



Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))